Site Search
Professionals 113 results
Capabilities 42 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
As society and business become even more digitalized, technology and intellectual property (IP) have become key focal points for businesses. Our Technology Antitrust Group combines the cross-practice and cross-office experience of our lawyers to assist clients in successfully navigating the dynamic convergence of technology, antitrust, and IP law. We understand the challenges presented by the ever-changing digital landscape and are committed to providing our clients with tailored solutions to address their specific needs.
Practice Area
Trade Secrets, Non Competes & Restrictive Covenants
Theft of trade secrets and other confidential information occurs all too frequently in today’s global, highly mobile, and competitive marketplace. In the course of advising clients, we have developed comprehensive, yet scalable, strategies for both mitigating against and responding to issues along the trade secrets protection spectrum, including helping position clients proactively before trade secrets theft occurs.
Experience 93 results
Experience
|October 24, 2024
Charlton Aria Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering
Experience
|September 23, 2024
Global Engine Group Holding Limited Announces Closing of $8 Million Initial Public Offering
Insights & News 642 results
Competition Corner
|November 22, 2024
|4 Min Read
Supreme Court’s Rejection of DOJ Appeal Could Shift the Landscape for Bid-Rigging Prosecutions
The U.S. Supreme Court has denied the request from the Department of Justice (DOJ) to review a ruling from the U.S. Court of Appeals for the Fourth Circuit that overturned the bid-rigging conviction of a former engineering firm executive because the indictment did not allege a per se antitrust violation.
Article
|November 21, 2024
|10+ Min Read
How To Safely Leverage AI In The Digital Assets Industry
This article was originally published in Law360. Reprinted with permission. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only.
Client Alert
|November 14, 2024
|7 Min Read
SEC Division of Examinations 2025 Priorities
On October 21, 2024, the U.S. Securities and Exchange Commission’s (the SEC) Division of Examinations (the Division) announced its annual list of examination priorities for 2025 (the Priorities), which are developed in consultation with various internal SEC divisions and offices. The priorities reflect practices, products, and services that the Division believes present heightened risks to investors or the integrity of the U.S. capital markets. The Priorities are not an exhaustive list of issues the Division intends to target in examinations. The Division’s examinations are also likely to address emerging risks, products, market events, and other investor concerns as they arise. In this alert, you will find a summary of the priorities for the SEC in examining registered investment advisers, registered investment companies, broker-dealers, and other market participants in 2025.
Other Results 32 results
Site Content
What Is the Price Range in an IPO?
The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price.
Site Content
Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA).
Site Content
Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table.